Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on IDEAYA Biosciences (IDYA – Research Report). The associated ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

The following is a summary of “Survival in uveal melanoma patients is linked to genetic variation at HERC2 SNP rs12913832,” published in the September 2024 issue of Ophthalmology by Gelmi et al. Uveal ...

The company will hold a groundbreaking ceremony Oct. 22 to celebrate the recent construction start of its new corporate ...

Background Paraneoplastic melanocytic proliferation (bilateral diffuse uveal melanocytic proliferation, BDUMP) is a rare but devastating disease that causes progressive visual loss in patients who ...

AVITA's large addressable market, high gross margins, and low valuation suggest the potential for 154% stock upside. Find out ...

Significant regulatory news last week included the US Food and Drug Administration (FDA) granting approval for Zevra ...

They could have received up to one prior systemic treatment as long as it was not an anti–CTLA-4, PD-1, PD-L1, or PD-L1 agent ...

Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populations.

eLife is a non-profit organisation inspired by research funders and led by scientists. Our mission is to help scientists accelerate discovery by operating a platform for research communication that ...